Compare IMOS & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMOS | OPK |
|---|---|---|
| Founded | 1997 | 2007 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.5M | 1.0B |
| IPO Year | N/A | 1995 |
| Metric | IMOS | OPK |
|---|---|---|
| Price | $30.49 | $1.26 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $2.28 |
| AVG Volume (30 Days) | 11.2K | ★ 3.7M |
| Earning Date | 11-11-2025 | 10-29-2025 |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $748,307,671.00 | $642,067,000.00 |
| Revenue This Year | $5.78 | N/A |
| Revenue Next Year | $10.84 | N/A |
| P/E Ratio | $139.81 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.78 | $1.11 |
| 52 Week High | $30.98 | $2.04 |
| Indicator | IMOS | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 61.45 | 36.18 |
| Support Level | $29.13 | $1.29 |
| Resistance Level | $30.65 | $1.34 |
| Average True Range (ATR) | 0.62 | 0.05 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 79.84 | 5.91 |
ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. It derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.